⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HIMS News
Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
accessnewswire.com
HIMS
YieldMax® ETFs Announces Weekly Distributions for Group 2 ETFs
globenewswire.com
ARKK
TSLA
AAPL
NVDA
AMZN
META
GOOGL
NFLX
COIN
MSFT
DIS
XOM
JPM
AMD
PYPL
MRNA
AI
MSTR
SNOW
ABNB
BABA
TSM
SMCI
PLTR
MARA
CVNA
HOOD
BRK.B
DKNG
RBLX
RDDT
GME
HIMS
CRCL
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Stockholders to Learn More About the Investigation
accessnewswire.com
HIMS
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
businesswire.com
HIMS
Bronstein, Gewirtz & Grossman, LLC Encourages Hims & Hers Health, Inc. (HIMS) Investors to Inquire about Securities Investigation
accessnewswire.com
HIMS
Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®
globenewswire.com
NVO
HIMS
Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026
globenewswire.com
HIMS
PharmaZee GLP-1 Prescription Information Updated as Novo Nordisk Raises Compounding Concerns and Consumer Interest in Telehealth Semaglutide Access Grows in 2026
globenewswire.com
NVO
HIMS
PharmaZee GLP-1 Review 2026: Evaluating Telehealth Semaglutide Platforms Amid Industry-Wide Compounding Scrutiny
accessnewswire.com
HIMS
Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
globenewswire.com
HIMS